Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12.

Authors

Guillermo Montalban-Bravo^#¹, Danielle Hammond^#², Courtney D DiNardo², Marina Konopleva², Gautam Borthakur², Nicholas J Short², Jorge Ramos-Perez², Veronica Guerra², Rashmi Kanagal-Shamanna³, Kiran Naqvi², Koji Sasaki², Elias Jabbour², Naveen Pemmaraju², Tapan M Kadia², Farhad Ravandi², Naval Daver², Zeev Estrov², Sherry Pierce², Hagop Kantarjian², Guillermo Garcia-Manero²

Affiliations

¹ Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. gmontalban1@mdanderson.org.
² Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

^# Contributed equally.

PMID: 33846541
DOI: 10.1038/s41375-021-01240-2

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
High-Throughput Nucleotide Sequencing / methods
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Myelomonocytic, Chronic / drug therapy*
Leukemia, Myelomonocytic, Chronic / genetics
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy
Myelodysplastic Syndromes / genetics
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax